Illumina, Inc.’s stock price takes a tumble, dropping 4.65% to a current $121.16 per share.

Illumina, Inc. (ILMN)

121.16 USD -5.91 (-4.65%) Volume: 1.62M

Explore Illumina, Inc.’s stock price of 121.16 USD, experiencing a trading session drop of -4.65%, with a trading volume of 1.62M, and a year-to-date percentage change of -12.98%. Dive into ILMN’s dynamic market performance.

Latest developments on Illumina, Inc.

Despite underperforming in comparison to its competitors on Monday, Illumina Inc. (NASDAQ: ILMN) has witnessed significant stock position movements. Key players such as International Assets Investment Management LLC, Perigon Wealth Management LLC, and WCM Investment Management LLC have increased their stock positions, purchasing a total of 32,814 shares. Additionally, RFG Advisory LLC and Raymond James Financial Services Advisors Inc. have also invested, buying 2,532 shares. However, Prime Capital Investment Advisors LLC has decreased its position in Illumina, while Ingalls & Snyder LLC has invested $2.35 million in the company.

Illumina, Inc. on Smartkarma

Analysts on Smartkarma, such as Baptista Research, have been covering Illumina Inc and providing valuable insights. In their report titled “Illumina Inc: The Inside Story of Steady Revenues and Strategic Expansions! – Major Drivers,” Baptista Research highlights that Illumina delivered mixed results for the previous quarter, with revenues below the analyst consensus. Despite lower revenue, non-GAAP net income surpassed expectations at $52 million or $0.33 per diluted share. The report also notes that while Core Illumina sequencing consumables revenue dropped 4% year-over-year, clinical sequencing consumables experienced a 10% growth, mitigating the decline.

A look at Illumina, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Illumina Inc has a mixed long-term outlook. While the company scores moderately on value and momentum, it falls short on factors like dividend and growth. The resilience score also indicates room for improvement. Despite this, Illumina Inc remains a key player in the genetic analysis industry, providing a wide range of products and services for genomic research centers, pharmaceutical companies, and academic institutions.

Overall, Illumina Inc‘s Smartkarma Smart Scores suggest that the company has potential for growth and value, but may need to focus on improving its resilience and dividend offerings. With a strong presence in the market for genetic analysis systems, Illumina Inc is well-positioned to continue serving a diverse range of clients in the biotechnology and pharmaceutical sectors.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma